“Digitalisation the key to efficient EU pharmaceutical regulation and easing of localised drug shortages”
Current EU regulatory systems too overwhelmed by paper, head of European association representing generics, biosimilars and value added medicines industries tells CPhI Worldwide online conference
Digitalisation is needed to update inefficient and paper-based European pharmaceutical regulatory systems as well as help ease localised medicines shortages in European Union member states, according to Adrian van den Hoven, Director General, Medicines for Europe in a keynote address at the CPhI Worldwide online conference Monday.
Generic and biosimilar medicines must become central to European healthcare policy as the region looks to rebuild in the wake of the COVID-19 pandemic, Medicines for Europe’s new president ad interim, Rebecca Guntern of Sandoz, tells Generics Bulletin in an exclusive interview.
The interview of Arun Narayan, Chairman ofthe Value Added Medicines Sector Group at Medicines for Europe, for the European Pharmaceutical Review on the importance of Value Added Medicines in achieving sustainable innovation, showing how existing molecules can offer various benefits for both patients & the healthcare sector when repurposed, reformulated, combined or paired with services or devices.
“EU Industry Welcomes New Schengen Strategy’s Green Lanes”
“Too much at stake in the EU pharma strategy to get it wrong: how the EU can deliver equitable access to medicines”
“EU Industry Welcomes New Schengen Strategy’s Green Lanes”
Interviu cu Adrian van den Hoven, director general Medicines for Europe
Asociația Medicines for Europe, al cărui director general sunteți, a sesizat în perioada pandemiei o serie de probleme, întâlnite aproape în toate țările UE, anume disfuncționalități în asigurarea stocurilor de medicamente și proceduri greoaie de achiziții de produse și echipamente medicale. Care sunt propunerile dv. pentru rezolvarea acestora?